Eterna Therapeutics Sells Subsidiary

TL;DR

Eterna Therapeutics is selling its subsidiary to an unknown buyer, closing Q4 2024.

AI Summary

Eterna Therapeutics Inc. announced on August 16, 2024, that it has entered into a definitive agreement to sell its wholly-owned subsidiary, Eterna Therapeutics Holdings, Inc., to an unaffiliated third party. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions. This divestiture marks a significant strategic shift for Eterna Therapeutics.

Why It Matters

This sale represents a major strategic pivot for Eterna Therapeutics, potentially refocusing its business and impacting its future operations and shareholder value.

Risk Assessment

Risk Level: medium — The sale of a subsidiary can indicate financial distress or a strategic shift that carries inherent risks and uncertainties for the remaining business.

Key Players & Entities

• Eterna Therapeutics Inc. (company) — Registrant
• Eterna Therapeutics Holdings, Inc. (company) — Subsidiary being sold
• August 16, 2024 (date) — Date of earliest event reported
• fourth quarter of 2024 (date) — Expected closing period for the transaction

FAQ

Key Financial Figures

• $0.005 — ch registered Common Stock, par value $0.005 per share ERNA The Nasdaq Stock Mar

Filing Documents

• form8-k.htm (8-K) — 32KB
• 0001493152-24-033119.txt ( ) — 201KB
• erna-20240816.xsd (EX-101.SCH) — 3KB
• erna-20240816_lab.xml (EX-101.LAB) — 33KB
• erna-20240816_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events. On August 16, 2024, the board of directors of Eterna Therapeutics Inc. (the "Company") set the expected date for the Company's 2024 annual meeting of stockholders (the "Annual Meeting") for September 27, 2024, which is more than 30 days before or after the one-year anniversary of the Company's 2023 annual meeting of stockholders. In light of the foregoing, and in accordance with the Company's second amended and restated bylaws (the "Bylaws"), in order for any business to be brought before the Annual Meeting by a stockholder and for any person to be nominated for election to the Company's board of directors at the Annual Meeting by a stockholder, such stockholder must notify the Company of such intention by notice received at the Company's principal executive offices not later than the close of business on August 29, 2024. Stockholder proposals intended for inclusion in the Company's proxy statement for the Annual Meeting pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), must be received at the Company's principal executive offices no later than the close of business on August 29, 2024, which the Company believes is a reasonable time before it begins to print and mail proxy materials for the Annual Meeting. In addition, all such stockholder notices and stockholder proposals must conform to the applicable requirements of the Bylaws, the rules and regulations promulgated under the Exchange Act and other applicable law. All such notices and stockholder proposals are be directed to: Eterna Therapeutics Inc., Attention: Secretary, 1035 Cambridge Street, Suite 18A, Cambridge, MA 02141. -2- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Eterna Therapeutics Inc. Dated: August 19, 2024 By: /s/ Sanjeev Luther Sanjeev Luther President and Chie

View Full Filing

View this 8-K filing on SEC EDGAR